» Articles » PMID: 33976241

Intra-host Evolutionary Dynamics of the Hepatitis C Virus Among People Who Inject Drugs

Overview
Journal Sci Rep
Specialty Science
Date 2021 May 12
PMID 33976241
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Most individuals chronically infected with hepatitis C virus (HCV) are asymptomatic during the initial stages of infection and therefore the precise timing of infection is often unknown. Retrospective estimation of infection duration would improve existing surveillance data and help guide treatment. While intra-host viral diversity quantifications such as Shannon entropy have previously been utilized for estimating duration of infection, these studies characterize the viral population from only a relatively short segment of the HCV genome. In this study intra-host diversities were examined across the HCV genome in order to identify the region most reflective of time and the degree to which these estimates are influenced by high-risk activities including those associated with HCV acquisition. Shannon diversities were calculated for all regions of HCV from 78 longitudinally sampled individuals with known seroconversion timeframes. While the region of the HCV genome most accurately reflecting time resided within the NS3 gene, the gene region with the highest capacity to differentiate acute from chronic infections was identified within the NS5b region. Multivariate models predicting duration of infection from viral diversity significantly improved upon incorporation of variables associated with recent public, unsupervised drug use. These results could assist the development of strategic population treatment guidelines for high-risk individuals infected with HCV and offer insights into variables associated with a likelihood of transmission.

Citing Articles

Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals.

Howe A, Rodrigo C, Cunningham E, Douglas M, Dietz J, Grebely J JHEP Rep. 2022; 4(5):100462.

PMID: 35434589 PMC: 9010635. DOI: 10.1016/j.jhepr.2022.100462.

References
1.
Stern A, Yeh M, Zinger T, Smith M, Wright C, Ling G . The Evolutionary Pathway to Virulence of an RNA Virus. Cell. 2017; 169(1):35-46.e19. PMC: 5787669. DOI: 10.1016/j.cell.2017.03.013. View

2.
Stern A, Bianco S, Yeh M, Wright C, Butcher K, Tang C . Costs and benefits of mutational robustness in RNA viruses. Cell Rep. 2014; 8(4):1026-36. PMC: 4142091. DOI: 10.1016/j.celrep.2014.07.011. View

3.
Grubaugh N, Smith D, Brackney D, Bosco-Lauth A, Fauver J, Campbell C . Experimental evolution of an RNA virus in wild birds: evidence for host-dependent impacts on population structure and competitive fitness. PLoS Pathog. 2015; 11(5):e1004874. PMC: 4439088. DOI: 10.1371/journal.ppat.1004874. View

4.
Pawlotsky J . Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. Gastroenterology. 2016; 151(1):70-86. DOI: 10.1053/j.gastro.2016.04.003. View

5.
Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P . Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999; 353(9171):2195-9. DOI: 10.1016/s0140-6736(98)12291-2. View